Dr. Agarwal’s Health Care Q1 FY27: ₹565-650 Cr

Stock snapshot and why it is in focus

Dr. Agarwal’s Health Care was indicated around ₹478, up ₹3.40 (0.72%) in the provided market snapshot. A separate line in the same information set states the current share price as ₹478.95. The focus has shifted to the company’s next quarterly results and to model-based estimates for Q1 FY27 (quarter ending June 2026). The dataset also flags a “Sales Growth” figure of 25.01%, though it does not specify the measurement period alongside that headline number. Along with estimates, the information includes multiple quarterly and annual financial series, plus operational and network scale indicators from an earnings call. Put together, these points offer investors a clearer basis to track revenue growth, operating profitability, and execution in the hospital network.

Q1 FY27 estimates: the range investors are tracking

The Uniresearch estimate for Dr. Agarwal’s Health Care’s Q1 FY27 revenue is ₹565-650 crore. This estimate is explicitly described as being based on a Q1 FY26 base of ₹501 crore. For profitability, the same estimate set gives a PAT range of ₹39-50 crore for Q1 FY27, versus ₹38 crore in Q1 FY26. The YoY growth rates presented in the table are +21.2% for revenue and +17.4% for PAT, using the stated base period. A 12-month target range of ₹551-613 (Uniresearch estimate) is also listed in the information.

Dr. Agarwal’s Health Care Q1 FY27 estimate table

When are the Q1 FY27 results expected?

The information set notes that Q1 FY27 results are expected in the July-August 2026 window, aligned with the broader NSE and BSE results season for the June 2026 quarter. Separately, another line states: “Upcoming Earnings date for Dr Agarwals Health Care Ltd. is 21st, May, 2026.” The dataset does not clarify whether the May date refers to a different reporting item, a prior schedule, or a different period label. What is clear from the text is that multiple timeline indicators are present, and investors typically track exchange filings for the final confirmed date.

Q1 FY26 performance: income, expenses, and PAT movement

For Q1 FY26, Dr Agarwals Health Care Ltd reported total income of ₹500.81 crore. This is described as a 35.7% QoQ rise from ₹369.07 crore (Q4 FY25) and a 22.3% YoY increase from ₹409.49 crore (Q1 FY25). Total expenses in Q1 FY26 were ₹447.21 crore, up 42.0% QoQ from ₹314.89 crore and up 16.9% YoY from ₹382.40 crore. Profit before tax (PBT) is listed at ₹53.60 crore for Q1 FY26, compared with ₹54.18 crore in Q4 FY25 and ₹27.08 crore in Q1 FY25. After tax of ₹15.54 crore, profit after tax (PAT) is stated at ₹38.06 crore, down 7.9% QoQ from ₹41.32 crore, while rising 108.9% YoY from ₹18.22 crore.

Key Q1 FY26 financial statement (as reported)

Operating line items from the quarterly highlights dataset

Another quarterly table (labelled “Quarter ended Jun 25” and showing comparisons) reports total revenue of ₹487.42 crore for Jun 25, versus ₹564.11 crore for Mar 26, and ₹403.49 crore for Jun 24. In the same table, operating income is listed at ₹64.91 crore (Jun 25) versus ₹84.79 crore (Mar 26) and ₹48.11 crore (Jun 24). Net income is shown as ₹30.05 crore (Jun 25) versus ₹39.71 crore (Mar 26) and ₹11.98 crore (Jun 24). Diluted normalized EPS is stated at ₹0.95 (Jun 25) versus ₹1.24 (Mar 26) and ₹0.43 (Jun 24). These figures provide an alternate view of operating and net lines alongside the total income and PAT series cited for Q1 FY26.

Quarterly trend: net sales and operating profit through Mar 2026

A separate quarterly series (all figures in ₹ crore) shows net sales rising from ₹281.02 crore (Mar 2025) to ₹347.86 crore (Mar 2026). Over the same period, operating profit is reported at ₹73.43 crore (Mar 2025) and ₹91.87 crore (Mar 2026), with interim values of ₹66.80 crore (Jun 2025), ₹68.86 crore (Sep 2025), and ₹80.04 crore (Dec 2025). Total expenditure in that table is ₹207.59 crore (Mar 2025) and ₹255.99 crore (Mar 2026). The same table lists other income and interest lines, including other income of ₹26.93 crore (Mar 2025) and ₹6.21 crore (Mar 2026), and interest of ₹20.90 crore (Mar 2025) and ₹18.66 crore (Mar 2026). Because these are presented as a standalone “Quarterly Result” series, readers typically cross-check period definitions and consolidation scope in the company’s filings.

Annual scale-up: net sales and operating profit over FY21-FY25

The annual table indicates net sales moving from ₹232.24 crore in Mar 2021 to ₹1,043.89 crore in Mar 2025. Operating profit in the same annual series rises from ₹32.94 crore (Mar 2021) to ₹241.16 crore (Mar 2025). The intermediate annual net sales values are ₹361.59 crore (Mar 2022), ₹597.64 crore (Mar 2023), and ₹835.06 crore (Mar 2024). The intermediate operating profit values are ₹86.13 crore (Mar 2022), ₹159.59 crore (Mar 2023), and ₹220.04 crore (Mar 2024). This multi-year climb is consistent with the company’s stated network expansion and higher procedure volumes.

Operational metrics: patients, surgeries, network, and regional mix

In an earnings call summary dated Aug 12, 2025, Dr. Agarwal’s Health Care reported total income of ₹501 crore for Q1 FY26 and PAT of ₹38 crore, with the note that PAT “more than doubled” YoY. The same summary lists EBITDA at ₹141 crore, up 28.9% YoY, with an EBITDA margin of 28.2% and a 140 basis point improvement. PAT margin is noted at 7.6%, expanding by 315 basis points. Operationally, the company reported serving over 7 lakh patients and performing nearly 79,000 surgeries during the quarter ending June 2025. It also stated it had 249 total facilities across 136 cities and five union territories, with a network described as 29 hubs and 220 spokes in India. South India is cited as the largest contributor with 65% of revenues, while the summary notes all regions delivered double-digit growth.

Corporate actions and other notable items in the dataset

The information set mentions that (AHCL) and Dr. Agarwal’s Eye Hospital (AEHL) approved a merger, with AEHL merging into AHCL, dated 13 Aug 2025. It also states that Dr Agarwals Health Care plans an IPO for $100 million. Separately, a “last earnings date” entry shows “Q0 FY26-27 | 21st, May, 2026” with revenue of ₹564 crore and net profit of ₹49 crore, alongside QoQ and YoY percentage changes (revenue: QoQ 6.46%, YoY 22.57%; net profit: QoQ 14.51%, YoY 17.41%). These items are presented as standalone data points without additional reconciliation to the other tables in the same text.

Market impact: what the numbers change for investors

At a stock level, the dataset’s price points around ₹478-₹478.95 frame the discussion around near-term expectations. For the next result cycle, the key watchpoint is whether revenue lands within the ₹565-650 crore Q1 FY27 estimate band and how the PAT range of ₹39-50 crore compares with the ₹38 crore Q1 FY26 base. Investors will also track whether operating leverage continues, given that Q1 FY26 showed expenses rising faster than income on a QoQ basis (42.0% vs 35.7%), while still delivering strong YoY profit growth. Margin indicators mentioned in the call summary, including EBITDA margin of 28.2% and PAT margin of 7.6%, provide reference points for profitability expectations. Operational disclosures like patient volumes, surgeries, and facility count help connect financial growth with on-ground capacity and utilisation. Corporate actions such as the AEHL into AHCL merger can also influence comparability across periods, depending on accounting treatment and consolidation scope.

Analysis: how to read Q1 FY27 estimates against history

The Q1 FY27 revenue estimate range implies growth over the stated Q1 FY26 total income base of ₹501 crore. The annual net sales series from FY21 to FY25 shows a steady ramp in scale, and the quarterly net sales series through Mar 2026 also indicates continued growth in recent quarters. At the same time, the Q1 FY26 expense step-up highlights why investors focus on cost control and operating margins, not just revenue. The dataset includes multiple reporting views (total income vs total revenue, and separate quarterly result series), so the cleanest comparison is within the same metric set and period definition. Operational metrics from the earnings call, such as 7 lakh patients and nearly 79,000 surgeries, offer context for volume-led growth. Finally, the 12-month target range of ₹551-613 is presented as an estimate, and readers typically align such targets with upcoming result dates and management commentary.

Conclusion

Dr. Agarwal’s Health Care is entering the Q1 FY27 results window with a revenue estimate band of ₹565-650 crore and a PAT estimate of ₹39-50 crore, based on the stated Q1 FY26 base. With the stock indicated near ₹478-₹478.95, attention is likely to remain on revenue delivery, profitability, and the consistency of operating margins highlighted earlier. The dataset points to a July-August 2026 indicative results window, while also listing May 21, 2026 as an upcoming earnings date, making exchange announcements important for confirmation. Investors will also track how reported operating metrics and any corporate actions affect like-for-like comparisons in the next set of numbers.